购物车
- 全部删除
- 您的购物车当前为空
Acumapimod (BCT-197) 是一种有口服活性的p38 MAP 激酶抑制剂,IC50值小于1 μM。
为众多的药物研发团队赋能,
让新药发现更简单!
Acumapimod (BCT-197) 是一种有口服活性的p38 MAP 激酶抑制剂,IC50值小于1 μM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 283 | 现货 | |
2 mg | ¥ 395 | 现货 | |
5 mg | ¥ 662 | 现货 | |
10 mg | ¥ 993 | 现货 | |
25 mg | ¥ 1,650 | 现货 | |
50 mg | ¥ 2,970 | 现货 | |
100 mg | ¥ 4,560 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 728 | 现货 |
产品描述 | Acumapimod (BCT-197) is an orally active inhibitor of p38α MAPK (IC50 <1 μM). |
靶点活性 | p38α:<1 μM |
体内活性 | Acumapimod 在以6 mg/kg剂量给予的情况下,能够提高感染流感病毒H1N1 A/PR/8/34的小鼠模型的生存率,并减少支气管肺泡灌洗液(BALF)中的巨噬细胞数量[1]。 |
动物实验 | In vivo, female BALB/c mice were infected intranasally with 150 pfu of influenza H1N1 A/Puerto Rico/8/34 and treated with Acumapimod(BCT197) (a closely related p38 MAPK inhibitor with an IC50 value of<1?μM, currently in clinical testing), dexamethasone or oseltamivir (Tamiflu) starting 24?h post infection. Body weight, bronchoalveolar lavage cells, cytokines, total protein and lactate dehydrogenase as well as serum cytokines were measured; a subset of animals was evaluated histopathologically[1]. |
别名 | BCT-197 |
分子量 | 385.42 |
分子式 | C22H19N5O2 |
CAS No. | 836683-15-9 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (129.73 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.